Drug profile · INN
evolocumab
REPATHA
- US status
- approved
- Patents linked
- 0
- News articles
- 2
Quick answer
evolocumab (REPATHA) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
Key facts
Related news
FDA Approves Repatha: Key Details on Amgen's Cardiovascular Drug
Repatha, recently approved by the FDA, is a groundbreaking treatment by Amgen for cardiovascular disease, targeting high cholesterol effectively.
FDA Approves Repatha for Pediatric Heterozygous Familial Hypercholesterolemia
The FDA has granted approval for Repatha, a groundbreaking treatment for pediatric patients suffering from heterozygous familial hypercholesterolemia, enhancing cholesterol control.
Frequently asked questions
What is evolocumab?
evolocumab (REPATHA) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for evolocumab?
REPATHA is a marketed brand name for evolocumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of evolocumab?
evolocumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.